Therapeutics News and Research

RSS

Novel computing platform models brain cell changes in autism

This technology introduces an advanced neural network model and specialized hardware architecture designed to analyze and identify synaptic dysfunctions related to Autism Spectrum Disorders and similar complex neurological conditions.

22 Sep 2026

Binghamton University scientists win seed funding for medical technologies

Two Binghamton University faculty members will receive seed funding through the State University of New York (SUNY) Technology Accelerator Fund (TAF), which provides grants to faculty inventors and scientists.

22 Sep 2026

Marine carbohydrates offer valuable new resources for drug development

The ocean contains diverse carbohydrates that could serve as valuable resources for drug development. Algae, marine animals and microorganisms produce polysaccharides and related molecules with structures that are uncommon on land, including distinctive sulfate patterns, sugar linkages and branched architectures.

22 Sep 2026

City of Hope develops adaptive plug-and-play CAR T technology to attack tumors

Researchers from City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the country, have developed a new "plug-and-play" technology that adds engineered molecules to chimeric antigen receptor (CAR) T cells after treatment, allowing scientists to better control the cells and redirect them to attack different types of cancer.

22 Sep 2026

Galimedix establishes Scientific Advisory Board for Alzheimer’s disease to guide development of novel oral drug candidate, GAL-101

Galimedix Therapeutics, Inc., a Phase 2 clinical-stage biotechnology company developing novel oral and topical neuroprotective therapies with the potential to revolutionize the treatment of serious brain and eye diseases, today announced the establishment of a dedicated Alzheimer's Disease Scientific Advisory Board (SAB).

From Galimedix Therapeutics, INC. 22 Sep 2026

New brain circuit discovery offers hope for panic disorder treatments

Our survival depends on brains that constantly search for danger and, if found, stay alert until it has passed.

21 Sep 2026

Stalled gut microbiome development triples risk for type 1 diabetes in children

Type 1 diabetes affects more than 9 million people worldwide, including 1.8 million children and adolescents.

21 Sep 2026

Big Picture Bio founded to identify, design and optimize promising cancer combination therapies

Big Picture Bio Ltd., has been founded to identify, design and optimize promising cancer combination therapies, using a generative world model to understand how tumors, immune cells and surrounding tissue interact across disease sites and patient subgroups.

From Big Picture Bio 18 Sep 2026

Researchers mine cobra toxins to uncover a membrane-disrupting antimicrobial peptide

Researchers combined toxin sequence mining with machine learning and deep-learning prediction tools to identify and experimentally test 14 antimicrobial peptide candidates derived from cobra cardiotoxins. Most candidates showed limited antibacterial potency, while CTX-p5 displayed moderate membrane-disrupting activity, revealing both the potential and current limitations of computationally guided venom peptide discovery.

17 Sep 2026

Salk scientists demonstrate B cells directly enhance killer T cell function

Cancer is the second leading cause of death in the United States, according to a 2026 Cancer Research Institute report. Cancer biologists are keenly aware of this statistic, as it drives them to innovations that revolutionize cancer care-innovations like immunotherapy.

17 Sep 2026

Study defines early-onset cirrhosis caused by fatty liver disease

Researchers at University of California San Diego School of Medicine have published the first study to define early-onset cirrhosis caused by metabolic dysfunction-associated steatotic liver disease (MASLD), a condition known as fatty liver disease.

16 Sep 2026

Study confirms continued effectiveness of antibodies and vaccines used to prevent RSV infections

An analysis of more than 60,000 respiratory syncytial virus (RSV) sequences from around the world found that viral variants associated with resistance to current RSV prevention tools remain rare, according to a study published Sept. 16 in Nature.

16 Sep 2026

New AACR report outlines future of cutting-edge cancer research

Today, the American Association for Cancer Research (AACR) released the 16th edition of its annual Cancer Progress Report.

16 Sep 2026

Novel blood test could detect pancreatic cancer at its earliest stages

Researchers at City of Hope, one of the largest and most advanced cancer research and treatment organizations in the country, led the development of a new, investigational blood test that could detect pancreatic cancer at its earliest stages, when the disease is more treatable and potentially curable.

16 Sep 2026

Study illuminates the link between the Epstein-Barr virus and multiple sclerosis

A new study illuminates the connection between the Epstein-Barr virus (EBV) and multiple sclerosis (MS), pointing to a causal role for reactivation of the virus in triggering MS attacks in people with certain genetic risk factors.

16 Sep 2026

Insilico Medicine launches AI initiative to develop longevity vaccines

Insilico Medicine, a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced Longevity Vaccines, a research initiative developing treatments that direct a patient's own immune cells to eliminate the earliest cellular drivers of age-related disease.

15 Sep 2026

Genetic variant accelerates Huntington’s disease onset by over a decade

A new study has revealed why some people with Huntington disease develop symptoms 10 to 12 years earlier and experience a more aggressive form of the disease.

15 Sep 2026

Optimizing respiratory virus research workflows with VACUBOY

UTS researchers utilize the VACUBOY and VACUSAFE systems to enhance respiratory health studies, streamlining cell culture workflows and improving productivity.

15 Sep 2026

Final results from PAPILLON trial confirm long-term survival in a subset of lung cancer

Final results from the landmark PAPILLON trial, which changed the standard of care for a difficult-to-treat rare form of lung cancer, confirm that amivantamab, when added to chemotherapy, provides durable clinical benefit and the longest median overall survival reported to date for people with the disease.

15 Sep 2026